Nocturne Gaetane, Cornec Divi, Seror Raphaèle, Mariette Xavier
INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, rue Gabriel Peri, 94270 Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, rue du générale Leclerc, 94270 Le Kremlin-Bicêtre, France.
Department of Rheumatology, CHRU Brest, rue Boulevard Tanguy Prigent, 29609 Brest, France; EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, 5 Foch - CHU Morvan - BP 824, 29609 Brest, France.
Rheum Dis Clin North Am. 2016 Aug;42(3):407-17. doi: 10.1016/j.rdc.2016.03.001. Epub 2016 Jun 21.
The management of patients suffering from primary Sjögren syndrome (pSS) has long been mainly symptomatic and demonstration of effectiveness of systemic drugs was lacking. However, progress made in the understanding of pSS pathogenesis has allowed moving into a more targeted approach to therapeutic intervention. Given the key role of chronic B-cell activation, B-cell target therapies were the first candidates. New pathways are currently being investigated, including costimulation and ectopic germinal center. In this review, we summarize the current evidence regarding B-cell targeted and anti-TNF therapies and provide an overview of promising drugs in the pipeline.
原发性干燥综合征（pSS）患者的管理长期以来主要是对症治疗，且缺乏系统性药物有效性的证明。然而，对pSS发病机制认识的进展使得治疗干预能够转向更具针对性的方法。鉴于慢性B细胞活化的关键作用，B细胞靶向治疗成为首选。目前正在研究新的途径，包括共刺激和异位生发中心。在本综述中，我们总结了关于B细胞靶向治疗和抗TNF治疗的现有证据，并概述了正在研发中的有前景的药物。
